Genprex, Inc. (LON:0A8I)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 3.74M -13.8% |
| Revenue (ttm) | n/a |
| Net Income | -12.48M |
| EPS | -27.77 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,287 |
| Average Volume | 25,913 |
| Open | 2.160 |
| Previous Close | 2.200 |
| Day's Range | 2.050 - 2.260 |
| 52-Week Range | 1.724 - 54.600 |
| Beta | -0.80 |
| RSI | 42.76 |
| Earnings Date | Apr 1, 2026 |
About Genprex
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), ... [Read more]
News
Genprex Advances Diabetes Gene Therapy Program With Preclinical Milestones
(RTTNews) - Genprex, Inc. (GNPX) announced on Wednesday that it has an update on its clinical program for GPX-002, the gene therapy it's developing for diabetes, making strides in both Type 1 and Type...
Genprex Provides Clinical Update on Diabetes Gene Therapy Program
Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDA...
Genprex's Gene Therapy GPX-002 Rejuvenates Beta Cells In Type 2 Diabetic Animal Studies
(RTTNews) - Genprex Inc. (GNPX) reported positive preliminary preclinical results for its diabetes gene-therapy candidate GPX-002, showing in-vivo proof-of-concept in both Type 2 diabetic non-human pr...
Genprex Reports Positive Preclinical Data For Diabetes Gene Therapy Candidate GPX-002
(RTTNews) - Genprex, Inc. (GNPX) on Tuesday reported preliminary preclinical data showing its diabetes gene therapy candidate GPX-002 improved glucose control in Type 2 diabetes animal models.
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates GPX-002 Rejuvenated Exhausted Beta Cells and Normalized Glucose...
Genprex (GNPX) Shares Positive Acclaim-1 Trial Data for Lung Cancer Therapy
Genprex (GNPX) Shares Positive Acclaim-1 Trial Data for Lung Cancer Therapy
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
Phase 1 Study in Non-Small Cell Lung Cancer Combined Reqorsa® Gene Therapy with Tagrisso® AUSTIN, Texas , Nov. 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a cli...
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer Acclaim-1 and Acclaim-3 Clinical Trials Supported by FDA Fast Track Designation AUSTIN, Texas , Nov. 19...
Genprex (GNPX) Secures Patent for Gene Therapy Combo with PD-L1 Antibodies
Genprex (GNPX) Secures Patent for Gene Therapy Combo with PD-L1 Antibodies
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Strengthens Intellectual Property Portfolio and Provides Protection for Therapeutic Combination in Acclaim-3 Clinical Trial AUSTIN, Texas , Nov. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or th...
Genprex (GNPX) Receives European Patent Intent for Cancer Gene Therapy
Genprex (GNPX) Receives European Patent Intent for Cancer Gene Therapy
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Adds to the Previously Granted Patents Covering the Use of REQORSA in Combination with Immune Checkpoint Inhibitors Strengthens Patent Estate and Provides Additional Protection in Large Market AUSTIN,...
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
$3.4 million upfront with up to an additional $6.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants AUSTIN, Texas , Oct. 28, 2025 /PRNewswire/ -- Genprex,...
Genprex (GNPX) Reports Promising Preclinical Results for Lung Cancer Therapy
Genprex (GNPX) Reports Promising Preclinical Results for Lung Cancer Therapy
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Combining REQORSA with Alectinib Further Increased Apoptosis and Improved Treatment Outcome...
Genprex launches offering to raise up to $8.1M
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
$2.7 million upfront with up to an additional $5.4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants AUSTIN, Texas , Oct. 23, 2025 /PRNewswire/ -- Genprex,...
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Research Suggests that REQORSA May Be an Effective Treatment in Patients Progressing on Ale...
Genprex (GNPX) Shares Jump 41% After Hours Following New Cancer Therapy Data
Genprex Inc. (NASDAQ: GNPX) shares rose 41.39% to $0.36 in after-hours trading on Tuesday. Check out the current price of GNPX stock here . Company Announces Conference Presentation The Texas-based c...
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer AUSTIN, Texas , Oct. 14, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (N...
Genprex (GNPX) Files to Sell 25 Million Common Shares
Genprex (GNPX) Files to Sell 25 Million Common Shares
Genprex files to sell 25M shares of common stock by selling shareholders
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 2, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stag...
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
Strengthens Intellectual Property Estate for REQORSA Oncology Program with Immune Checkpoint Inhibitors AUSTIN, Texas , Aug. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ...
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
Company Achieves Multiple Clinical Development Milestones in 2025 Patient Treatment Continues in Two Lung Cancer Clinical Trials AUSTIN, Texas , Aug. 4, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" o...